Posted on 02/06/2009 in Pharmaceutical Company Product News Bayer HealthCare has asserted it is committed to researching Nexavar (sorafenib) for a range of solid tumour types.
The company and Onyx Pharmaceuticals have started to enrol patients who have non-squamous non-small cell lung cancer (NSCL) and have been unresponsive to other treatments into an international phase III clinical trial to evaluate the tablets.
Europe, Africa, South America, North America and the Asia-Pacific region are all locations where the 120 sites of the study will be based.
Vice-president of Nexavar's clinical development division Dr Dimitris Voliotis explained the drug has already proved to be effective treating kidney and liver cancer.
"Based on strong findings in the phase II trials, Bayer and Onyx moved to the next phase of development and initiated this phase III trial evaluating Nexavar in NSCLC," he said.
Last week, Bayer Schering Pharma released data from studies of its potent oral multi-kinase inhibitor BAY 73-4506.
It is being examined against multiple tumour types and lead investigator Professor Tim Eisen said he is "encouraged" by the results so far.Other news stories from 02/06/2009
Read more in the Zenopa News Archive
How this news is generated
|
